NCT03889275View on ClinicalTrials.gov

A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 24, 2019

Primary Completion Date

November 19, 2021

Study Completion Date

December 12, 2022

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

MEDI5395

Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.

BIOLOGICAL

Durvalumab

Participants will receive IV infusion of durvalumab as stated in arm description.

Trial Locations (10)

10065

Research Site, New York

14263

Research Site, Buffalo

15232

Research Site, Pittsburgh

27599

Research Site, Chapel Hill

55905

Research Site, Rochester

85054

Research Site, Phoenix

92093

Research Site, La Jolla

02903

Research Site, Providence

LS9 7TF

Research Site, Leeds

SW3 6JJ

Research Site, London

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT03889275 - A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors | Biotech Hunter | Biotech Hunter